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  INTRODUCTION 
 Hypertension is one of the most common worldwide diseases afflicting 
humans. Because of the associated morbidity and mortality and the cost to society, 
hypertension is an important public health challenge. Over the past several 
decades, extensive research, widespread patient education, and a concerted effort 
on the part of health care professionals have led to decreased mortality and 
morbidity rates from the multiple organ damage arising from years of untreated 
hypertension. Hypertension is the most important modifiable risk factor for 
coronary heart disease (the leading cause of death in North America), stroke (the 
third leading cause), congestive heart failure, end-stage renal disease, and 
peripheral vascular disease. In this context, assessment of subclinical organ 
damage has become a key element in evaluating hypertensive patients.  
Recognition of microalbuminuria stemmed from diabetes research 4 decades 
ago.  According to National Kidney Foundation microalbuminuria is defined as a 
Urine Albumin Excretion Rate (UAER) of approximately 30-300mg/d in  non 
ketotic sterile urine. The association between microalbuminuria and hypertension 
was described long time ago.  In 1976, Parving et al highlighted the relation 
between microalbuminuria and the severity of hypertension. A renewed interest in 
microalbuminuria and essential hypertension occurred in late 1980s when several 
studies pointed out the importance of microalbuminuria as an important risk factor 
 
 
 
 
for renal & cardiovascular disease in patients with diabetes and hypertension. 
Microalbuminuria possibly reflects a state of increased renal endothelial 
permeability and is an easily measured marker of rather diffuse endothelial 
dysfunction, low grade inflammation and vascular disease burden. Therefore 
screening for microalbuminuria and follow up of patients is now a general practice 
in some countries, but not all.   
  
 Microalbuminuria can be diagnosed on the basis of three positive tests – Albumin 
creatinine ratio; urine albumin excretion rate or a combination of both.  Although 
the determination is yet to be fully standardized, current assessment methods are 
sufficiently robust to warrant periodic assessment for all hypertension patients.   
Great importance has been given to microalbuminuria as a prognostic 
marker of cardiovascular and/or renal risk in hypertensives.Studies have 
demonstrated an ongoing association of microalbuminuria with cardiovascular 
events and kidney lesions, that is, the higher the urinary albumin excretion the 
greater the risk to develop these conditions . 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
 
1. To  detect prevalence of microalbuminuria in  systemic hypertension. 
 
2. To document the involvement of various organ systems in these patients and 
study relationship of microalbuminuria to target organ damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
The phenomenon of hypertension  was 1st characterized at the turn of the 
century when Riva Rocci developed the prototype of modern sphygmomanometer 
and so allowed routine measurement of BP. Korotkov then perfected the 
sphygmomanometric technique by describing the sounds heard over brachial artery 
as the pressure in the cuff is reduced1. 
Defining Hypertension: 
Blood pressure is a continuous variable with no absolute dividing line 
between normal and abnormal values.  The best operational definition is “the level 
at which the benefits (minus the risks & costs) of action exceeds the risks and costs 
(minus benefits) of inaction.  In past several decades, the levels at which definite 
HT is defined as beginning have changed from > 160/95mms of Hg to > 140/90 
mms of Hg.  The definition of HT for home & ambulatory measurements are 
different: BP > 135/85 mms of Hg for 24hours ambulatory monitoring or home 
monitoring is the usual level considered to be where HT starts2.    
 
 
 
 
 
 
 
Classification of BP: (For adults aged 18 yrs or older) 
JNC – VII Classification: (American Medical Association.) 34 
BP Classification  Systolic BP( mm 
Hg) 
Diastolic BP( mm 
Hg) 
Normal  <120 <80 
Pre hypertension  120 – 139 80 – 89 
Stage I HT 140 – 159 90 – 99 
Stage II HT  >  160 >  100 
ESH – ESC Guidelines: 2003: for management of HT. [European Society of 
HT – European Society of Cardiology]. 
 
Category  
Systolic BP( mm Hg) 
Diastolic BP (mm Hg) 
Optimal  <120 <80 
Normal  <130 <85 
High Normal  130 – 139 85 – 89 
Hypertension  140- 159 90 – 99 
Stage 1  
Stage2   160 – 179 100 – 109 
 
 
 
 
Stage 3 > 180 110 
Isolated systolic HT  > 140 90 
 
The JNC VII classification is based on the mean of 2 or more properly 
measured seated BP readings  on each of 2 or more office visits3.   
Natural history of untreated Hypertension: 
In untreated Hypertensives, with age, the systolic BP increases and diastolic 
BP falls.  The risks associated with HT are much more strongly related to levels of 
systolic BP, than to Diastolic BP in those over the age of 50 – 60 years.   
Symptoms and Signs: 
Uncomplicated HT is almost always asymptomatic so that patients may be 
unaware of the consequent progressive cardiovascular damage for as long as 10 – 
20years.   Symptoms often attributed to HT → Headache, Tinnitus, Palpitation, 
Dizziness and fainting – may be observed just as commonly in normotensive  
population.   
Headache is characteristic of only severe HT:  Such headaches are localized 
to occipital region and are present when the patient awakens in the morning but 
subsides spontaneously after several hours.   
 
 
 
 
Complaints referable to vascular disease are the following : 
Epistaxis, hematuria, blurring of vision  owing to retinal changes, episodes 
of weakness/ dizziness due to transient cerebral ischemia, angina pectoris, 
dyspnoea due to cardiac failure.  Pain due to dissection of aorta / leaking aneurysm 
is a rare presenting symptoms2.   
Course of untreated HT: 
The relation between increasing BP and cardiovascular mortality is direct, 
continuous and independent of other risk factors.  The findings in long follow up of 
subjects screened for MRFIT study have been confirmed by meta analysis of 
relationship between BP and cardiovascular mortality in almost one million adults 
in 61 prosepective observational studies.  Each 20 mm Hg rise in systolic BP or 10 
mm Hg rise in diastolic BP is associated with > a 2 fold increase in mortality from 
stroke and a 2 fold increase in mortality from CAD.   
Risk  Stratification  In  Patients  With  Hypertension : 
 
Major Risk factors Target organ Damage 
Smoking Heart diseases, LVH 
Dyslipidemia Angina / Prior MI 
 
 
 
 
Diabetes mellitus Prior coronary 
revascularisation 
Age > 60 years Heart failure 
Sex (male and  post menopausal female) Stroke or TIA 
Family history of Cardiovascular disease Nephropathy 
Women >65 years and  men > 55 years 
Peripheral arterial disease  
Retinopathy  
Risk  Stratification And Treatment : 
Bloodpressure 
stages  
Risk Group A Risk Group B Risk Group C 
 ( mm Hg) No risk factors  
No TOD*  
No CCD** 
At least 1 risk 
factor 
Not including  
DM 
NoTOD / CCD 
TOD/ CCD and 
or DM with  or 
without other 
risk factor  
High normal  ( 
130 – 139 / 85 – 
89 ) 
Life style 
modification  
Life style 
modification  
Drug therapy 
Stage I ( 140 – 
159/ 90 – 99)  
Life style 
modification 
upto (12 months)
Life style 
modification  
(upto 6 months) 
Drug therapy  
Stage II (>160/ 
>100)  
Drug therapy  Drug therapy  Drug therapy  
 
 
 
 
 
* Target organ damage 
** Clinical cardiovascular disease  
 Complications of Hypertension : 
The biological aggressiveness of given level of HT varies among 
individuals. The pathological  hall marks of uncontrolled HT is accelerated 
atherosclerosis.  If untreated, about 50% of hypertensive patients die of Coronary 
Artery disease (CAD) or  Congestive Cardiac Failure (CCF).  33% die of stroke; 
10 – 15% die of Renal Failure.  The role of HT in producing underlying vascular 
damage that leads to these cardiovascular catastrophes is usually underestimated.  
Death is usually attributed to stroke or myocardial infarction instead of  to the HT 
that was largely responsible.  The inherent propensity to induce vascular damage 
can best be ascertained by examination  of eyes, heart and kidney.  
FUNDOSCOPIC EXAMINATION  
Vascular damage in the fundus reflect both hypertensive retinopathy and 
atherosclerotic retinopathy.Fundoscopic findings provide one of the best indication 
of the duration of HT and of prognosis.  A useful guide is the Keith – Wagener – 
Barker classification of the fundoscopic changes1.   
 
 
 
 
Grade I – Localised spasm or narrowing of arteriolar lumen, Arterial 
tortousity (“ Silver Wiring”).   
Grade II – Arteriovenous nicking due to sclerosis of the adventitia and /or 
thickening of the arteriolar wall.   
Grade III – Haemorrhage and exudates due to rupture of small vessels.    
Grade IV – Papilloedema  
Grade III and IV changes are clearly indicative  of an accelerated malignant 
form of HT.   
Cardiac Involvement: 
HT places increased tension on the left ventricular myocardium that is 
manifested as left ventricular hypertrophy (LVH) which accelerates the 
development of atherosclerosis within the coronary vessels.  The combination of 
increased demand and lessened supply increases the likelihood of myocardial 
ischemia and there by leads to a higher incidence of myocardial infarction, 
arrhythmias and congestive heart failure (CCF)  in hypertensive patients2.   
Abnormalities in Left Ventricular Function: 
Even before LVH develops, changes in both systolic and diastolic function 
can be seen.  Those patients with minimally increased left ventricular muscle mass 
 
 
 
 
may have super normal contractility with a high percentage of fractional shortening 
and increased wall stress.  The earliest functional cardiac changes in  hypertension 
are in left ventricular diastolic function  with lower E/A ratios and longer 
isovolumetric  relaxation  time.   With increasing  hemodynamic load, either 
systolic or  diastolic dysfunctions may evolve and progress to different forms of  
congestive heart failure.  In addition, impaired coronary flow reserve and thallium 
perfusion may be observed in hypertensive patients without obstructive coronary 
disease.   
Left ventricular hypertrophy (LVH) : 
LVH results from chronic elevations in arterial pressure that causes cardiac 
myocyte hypertrophy and remodelling of the coronary resistance vessels.  This 
leads to perivascular fibrosis of the intramyocardial arteries and arterioles.  LVH is 
necessary and protective upto certain point.  Beyond that point, a variety of 
dysfunctions accompany LVH including lower coronary vasodilatory capacity, 
depressed left ventricular wall mechanics and abnormal left ventricular diastolic 
filling pattern.   LVH is identified by ECG in only 5 – 10% of hypertensive 
patients.  LVH is found by echocardiography in nearly 30% of unselected 
hypertensive adults and upto 90% of persons with severe hypertension.   
 
 
 
 
 
Heart failure: 
The various alterations in systolic and diastolic function seen with LVH 
obviously can progress to congestive cardiac failure (CCF).  A 20mm Hg 
increment in systolic BP conferred a 56% increased risk for CCF in Framingham 
Cohort.  For many undertreated or untreated Hypertensives, LVH is an important 
intermediate step resulting in Hypertensive heart disease with impaired LV filling 
and increased ventricular stiffness. This type of heart failure (seen in 40% of 
hospitalized patients with antecedent history of hypertension) is called Diastolic 
Dysfunction.  The more common type of “Systolic Dysfunction” associated with a 
reduced LV ejection fraction most often is due to previous myocardial infarction.  
(For which HT also is an important risk factor).   
Coronary artery disease: 
Hypertension is a major risk factor for myocardial infarction and ischemia.   
Prevalence of silent MI is significantly increased in hypertensive subjects and they 
have a greater risk for mortality after an initial myocardial infarction2.   
Once MI occurs, prognosis is affected by both the pre existing and 
subsequent BP.  An increase in post – MI mortality has been noted among those 
whose blood pressure fell significantly, presumably a  reflection of poor pump 
 
 
 
 
function.  If the blood pressure of these subjects remained elevated, the prognosis 
was even worse, like representing a severe load on the damaged myocardium.   
Renal  Function : 
Both structural damage and functional derangement reflecting 
intraglomerular hypertension often reflected by  microalbumiuria can be found in 
most hypertensive  patients.  Microalbuminuria in hypertensive patients has been 
correlated with LVH and corotid artery thickness.  As hypertension induced 
nephrosclerosis proceeds, plasma creatinine levels begin to rise and eventually 
renal insufficiency may develop.  Any agent or group of agents that adequately 
lowers BP to levels < 130/85 mm Hg will slow the progression of nephropathy.    
Cerebral involvement: 
Hypertension may accelerate cognitive decline with age.  Hypertension, 
particularly systolic is a major risk factor for both ischemic stroke and intracerebral 
haemorrhage.  Cerebral white matter lesions are a common finding by brain MRI 
seen in 41% of asymptomatic, middle aged hypertensive patients than in 
normotensive subjects. 
 
 
 
 
 
 
Evaluation Of A Hypertensive Patient: (JNC 7 recommendations)   
Physical examination: 
Appropriate measurement of BP, verification in the contralateral arm, 
examination of optic fundi, body mass index calculated as weight in kilograms 
divided by square of height in metres (Measurement of waist circumference also 
may be useful). Also,auscultation for carotid, abdominal and femoral bruit, 
palpation of thyroid gland, thorough examination of cardiovascular and respiratory 
system, examination of abdomen for enlarged kidney, masses and abdominal aortic  
pulsations., palpations of lower extremities for oedema and pulses and a thorough 
neurological assessment.  is important.  
 
Laboratory tests and other diagnostic procedures 
Basic tests: 
I.  Always Included: 
1. Urine analysis: Protein, Blood, Glucose, Microscopy 
2. Haematocrit 
3.  Blood  glucose 
4. S. Creatinine and / or BUN  
 
 
 
 
5. Lipid profile (after 9 – 12 hr fast) – that includes HDL – Cholesterol, 
LDL – Cholesterol, Triglycerides. 
6. Electrocardiogram 
European society of HT – European Society of Cardiology also include the 
following investigations: 
Optimal tests: 
1. Urine analysis excretion or albumin creatinine ratio. More extensive testing 
for identifiable causes is not indicated generally unless BP control is not 
achieved.   
2. WBC Count,  
3. Serum Phosphate 
4. Chest X – ray.   
5.  Echocardiogram.   
More extensive testing for identifiable causes is not indicated generally 
unless BP control is not achieved.   
Hence it is evident that urine albumin excretion is one important parameter 
which should ideally be included in the evaluation of  a hypertensive patient.   
 
 
 
 
 
 
 
MICROALBUMINURIA 
Concepts and definition: 
 Microalbuminuria is defined as UAER of approximately 30 – 300 mg/d (24 
hour urine albumin excretion rate) in a  samples of nonketonic sterile urine 34-39.  
Ideal is the first voided, mid stream morning sample (5ml sample).   
ADA and NKF (American Diabetes Association and National Kidney 
Foudation) define microalbuminuria as an albumin creatinine ratio between 30 – 
300 μg/mg in both men and women7.  Sex specific ACR cutpoints: > 17 μg/mg in 
men, >25 μg/mg in  women.   
24 hour urine albumin excretion rate: 30 – 300 mg/d.  
 Overnight urine albumin excretion rates: 20 - 200μg/hr.  
Albumin creatinine ratio :  2.5 – 25mg/mmol (for men) or 
                                    3.5– 25 mg/mmol ( for women) 
                                    30 - 300μg/ mg in both men and women.   
 The 24 hour urine collection is considered to be the gold standard for 
assessing the low levels of UAER.The above values,though generally accepted, 
have been questioned by some authors .40-43 
 
 
 
 
 
 
 
Techniques of measurement and monitoring: 
Timed urine collections 24 hor or overnight remain the gold standard.  
Disadvantage 
This is cumbersome to the patient, in repeated large scale screening, this 
may become a significant problem.  For large scale screening use of albumin 
creatinine ratio in early morning urine is a convenient and reliable screening 
method.   
Potential confounders: 
Potential confounders in the detection of microalbuminuria are : 
Day – to –day variation of 40%.   
  
 False positives: 
Strenuous exercise, urinary tract infection, renal  disease.45-47 
Dipsticks exclusively detect albumin, sensitivity being for concentrations as low as 
250 mg/ml.   .Urine albumin cretatinine ratio can be used in random urine samples.  
Measurements correlate well with those obtained by classical way.  Urine albumin 
estimated by ELISA or immunoturbidometry and creatinine by Jaffe reaction , 
( rate blanked) , RIA and Nephelometry.   
 
 
 
 
 
 
Methods for detecting and measuring proteinuria 
Method  Description Coments 
Turbidimetric  Addition of 
Trichloroacetic or  
sulfosalicylic acids after 
colloid properties and 
produce turbidity to be 
read in densitometer 
(Benzathonium chloride 
also used) 
Imprecise, 
different 
readings for 
albumin and 
globulin 
Stick tests  Impregnated with 
indicator dye 
(bromocresol green ) 
which changes colour in 
presence or protein.   
Reacts poorly 
with globulin.  
Usual  clinical 
screening test.   
Nephelometric  Specific anti albumin 
antibody used.  
Measures 
albumin 
excretion, not 
total protein. 
 
Factors that Microalbuminuira helps to predict: 
Diabetic renal disease 
Diabetic Retinopathy 
Complications in pregnancy 
Cardiovascular mortality and morbidity in  
1. Type I diabetes 
2. Type II Diabetes 
3. Elderly Non diabetic people 
4. Non diabetic people with hypertension 
 
 
 
 
Microalbuminuria in Essential Hypertension. 
Microalbuminuria is found in a significant proportion of non diabetic 
population, particularly in association with essential hypertension, again is 
predictive of cardiovascular disease.  
Epidemiology: Between 2-10% of adult non diabetic population shows persistent 
microalbuminuria, with higher frequency in certain ethnic groups.  . Both 
microalbuminuria and overt proteinuria are associated with an increase in left 
ventricular mass, myocardial ischaemia, carotid artery thickness, overall 
cardiovascular morbidity and mortality6. 
Association of Microalbuminuria with other cardiovascular risk factors: 
 
Microalbuminuria and Hypertension    
  Patients with HT who show excess protein leakage tend to have greater 
evidence of cardiovascular comorbidities such as dyslipidemia and glucose 
intolerance, plus higher left ventricular mass, greater risk of hypertensive 
retinopathy and evidence of increased and more progressive atherosclerosis.  A 
raised UAE rate during acute MI is also predictive of inhospital mortality and is 
independent of other systemic markers.  
  
 
 
 
 
 
Mechanisms of Association between microalbuminuria and hypertension: 3 
mechanisms are described  
     
1. Increased intraglomerular pressure 48 
2. Intrinsic glomerular damage causing changes in glomerular filtration  
barrier 50,51 
3. Tubular dysfunction resulting in prevention of normal reabsorption of 
filtered albumin.   
 
Microalbuminuria and Hypertension – Implications for treatment 
Studies in essential hypertensives with microalbuminuria have shown that 
ACEI have a greater capacity to decrease microalbuminuria than other group of 
antihypertensives. ARBs may show similar benefits from the point of view of renal 
microcirculation6. 
Role of ACEI Drugs: 
Most studies have reported greater reduction in UAE rates in patients with 
hypertension with microalbuminuria using ACE inhibitors compared with other 
antihypertensive drugs such as β blockers, α Blockers and CCBs. The reason for 
the apparent advantage of ACEI over other classes may relate to specific effects on 
 
 
 
 
the renal microcirculation thereby reducing intraglomerular pressure and protein 
leakage. 
What is not clear is whether reduction in UAE rates in patients with essential 
hypertension relates to long term renal and more importantly cardiovascular 
protection. This issue was addressed in part by HOPE study.  A randomized 
Control Trial of over 9000 patients at high cardiovascular risk – they were either 
diabetic (around 35000 patients) or non diabetic with a previous vascular event. 
They were randomized to receive ACEI , Ramipril or placebo and followed for 
five years. During the study they could have any other treatment including 
antihypertensives. There was clear separation in the composite end point of 
cardiovascular mortality, MI and stroke, and also in each of these variables 
independently in favour of ACEI. There was also evidence for renal protection in 
the diabetic subgroup. They also demonstrated cardiovascular protection with 
ACEI. But the HOPE study did not specifically look at the relationship between 
mircoalbuminuria and cardiovascular risk and whether improvement in 
microalbuminuria will reduce that risk. The evidence for ACE inhibition being 
cardiovascular protective is also supported by recent data from the Perindopril 
Protection Against Recurrent Stroke Study (PROGRESS) using ACEI Perindopril. 
 
 
 
 
 
 
Angiotensin II receptor Blockers: 
Recently few studies have been published which report renal protection by 
using ARBs from the point of view of further progression of overt nephropathy or 
conversion from incipient to overt nephropathy. Data in non diabetic population is 
limited. A study comparing ARB Losartan and Enalapril showed that the former 
reduced mircoalbuminuria as affectively as the latter. To date, there is no evidence 
of cardio protection with these agents. 
LEFT VETNRICULAR HYPERTROPHY 
Electrocardiography 
Sokolow – lyon index: SV1 + (RV5 – or RV6) > 3.5mv.    R avL > 1.1mv. 
Romhilt Estes Point score system : 
Any limb lead R wave or S wave > 2.0mv     3 points 
or SV1 or SV2 > 3.0mV 3 points 
or RV5 or RV6 > 3.0mV 3 points 
ST – T wave abnormalities (no digitalis) 3 points 
ST – T wave abnormalities (digitalis therapy) 1 point 
Left Atrial abnormality 3 points 
Left Axis Deviation (> 30o) 2 points 
QRS duration > 90 msec 1 point 
Intrinsicoid deflection in V5 or V6 > 50msec 1 point 
 
A score of 5 points is  considered  as LVH. 
 
 
 
 
 
 
ECHOCARDIOGRAPHY 
 Hypertensive heart disease is characterized by concentric left ventricular 
hypertrophy with increased wall thickness and non dilated chamber. Hypertrophy 
is symmetric. LV mass can be calculated from M mode data. LV mass is the total 
weight of myocardium.  
Dimensions needed :     ST – Septal thickness (0.6 – 1.1) 
                             PWT – Posterior wall thickness (0.6 – 1.1) 
                             LVID - Left ventricular internal dimension at end diastole.   
LV Mass = 0.80 X [1.04 (ST + PWT + LVID)3 – LVID3] + 0.6g 
Relative wall thickness = Septal wall thickness + Posterior wall thickness 
     LV end diastolic diameter   
 
HYPERTENSIVE HEART DISEASE 
Left ventricular hypertrophy, 
Diastolic Dysfunction, systolic dysfunction (Long standing cases) 
 Aortic root dilatation 
Aortic valve sclerosis, 
Mitral Annnular calcification 
 LA enlargement; 
Atrial Fibrillation. 
 
 
 
 
 
Classification of Diastolic Dysfunction.    
Pathophysiology Normal Mild Mild-
Moderate 
Moderate Severe 
  ↓ 
Relaxation
↓ 
Relaxation 
↑ LVEDP 
↓ 
relaxation  
↓ 
Compliance 
↑ LVEDP 
↓ 
Relaxation 
↓↓ 
Compliance
↑↑ LVEDP
E/A Ratio 1 – 2 < 1 < 1 1 – 2 > 2 
IVRT msec 50-100 > 100 Normal ↓ ↓ 
DT msec 150-200 > 200 > 200 150-200 < 150 
E/A Ratio = Ratio of early to atrial transmitral velocity 
IVRT – Isovolumetric relxation time 
DT = Deceleration time of pulmonary venous diastolic flow phase 
 
Diastolic Function:  
 Diastolic dysfunction in hypertension is characterized by: 
Impaired early diastolic relaxation, prolonged Isovolumic Relaxation Time 
(IVRT); Reduced E velocity,  Reduced E/A ratio, Prolonged Deceleration slope.  
Systolic function 
Preserved early in the course of disease 
Segmental wall motion abnormalities are not seen unless co existing CAD is 
present.  
 
 
 
 
 
 
Assessment of LV systolic function 
1. Ventricular Volumes & Geometry, End Diastolic Volume (EDV) & End 
systolic volume (ESV) are measured (LVID or LV internal dimensions).  
Ejection Fraction (EF) = SV X 100.  Where SV = Stroke volume( SV = EDV-
ESV) 
                   EDV 
 
2. LV mass : is derived by multiplying the volume of myocardium times the 
specific density of cardiac muscle 
3. Fraction shortening (%) : N = Normal = 25 – 45% 
LVIDd – LVIDs X 100 
 LVIDd 
4. LV wall stress : Calculated by Relative Wall thickness (RWT) 
RWT = 2 x PWT PWT = Posterior Wall thickness 
   LVID  LVID = LV internal dimensions.  
 
An overview of the previous studies on this area: 
Results of large epidemiological studies have demonstrated that regardless 
of the severity of hypertension, the cost effectiveness of BP reduction by drug 
therapy is greater in presence of target organ abnormalities and/or comorbidities.  
In this context, assessment of subclinical organ damage namely LVH & peripheral 
atherosclerosis has become a key element in evaluating hypertensive patients. 
In a study conducted in department of Internal Medicine, University of 
Genova, Italy, consisting of 279 patients,  microalbuminuric patients were 21 times 
more likely to have both LVH and increased carotid IMT (P < 0.0001) as 
 
 
 
 
compared with those with normal albumin excretion.     In another study Berton et 
al showed that the presence of microalbuminuria strongly predicts mortality in 
patients with acute myocardial infarction even after adjusting all other 
confounders.  Increased UAE has also been related to peripheral atherosclerosis 
and increased carotid intima – media thickness (IMT).  In line with these findings, 
another preliminary study has found increased prevalence of asymptomatic 
cerebral vascular lesions as evidenced by NMR imaging in Hypertensive patients 
with microalbuminuria as compared with a group of well matched hypertensives 
with normal albuminuria.   Increased BP load and variability, higher uric acid 
levels, worse lipid profiles, Insulin resistance, Endothelial dysfunction, increased 
activity of RAAS18,19.     
Microalbuminuria possibly reflects a state of increased renal endothelial 
permeability and may be an easily measured marker of rather diffuse endothelial 
dysfunction, low grade inflammation and vascular disease burden.During 10years 
significant no. of scientific contributions have shown that increased UAER
 constitutes and independent predictor of atherosclerotic cardiovascular 
disease in non diabetic subjects, in elderly, in general population as well as in 
hypertensive patients   In addition, evaluation of UAER is one of the recommended 
laboratory tests proposed by European Society of Hypertension guidelines to 
assess target organ damage in Hypertensive subjects29.   
 
 
 
 
The first report on the association between microalbuminuria and increased 
risk of cardiovascular events in non diabetic subjects was published in 1988.  In 
Hoorn study, the relative risk of all cause mortality associated with 
microalbuminuria and peripheral arterial disease was about 5 times higher among 
hypertensive than normotensive subjects    In the prevention of Renal and Vascular 
End stage disease study, microalbuminuria in addition to conventional 
cardiovascular risk indicators was independently associated with ischemic 
electrocardiographic abnormalities reflecting underlying coronary artery disease29.   
Interestingly, in a cohort of elderly hypertensive individuals without 
previous cardiovascular complications, augmented UAER was predictor of adverse 
cardiovascular events, irrespective of BP levels.  In a group of subjects during the 
first week after an acute ischemic event, elevated UAER proved to be a significant 
predictor of 1year mortality, independent of the other cardiovascular risk factors.  
Even minimal increments of UAER could be clinically significant in hypertensive 
patients. In HOPE study (Heart Outcomes Prevention Evaluation Study) with a 
median of 4.5 years of follow up, any degree of mciroalbuminuria was proven to 
be a risk factor for cardiovascular events in individuals with or without diabetes.  
The risk increases with the urine albumin creatinine ratio; starting well below the 
microalbuminuria cut off; even as low as 0.5mg/mmol.  For every 0.4mg/mmol 
increase in albumin – to – creatinine ratio, the adjusted hazard of major 
 
 
 
 
cardiovascular events augmented by 5.9%.  Albumin creatinine ratio of 
>0.65mg/mol was associated with augmented risk of developing fatal and non fatal 
ischemic heart disease.  In the light of most recent data from the LIFE study 
(Losartan Intervention for Endpoint Reduction Study) in non diabetic 
hypertensives with LV hypertrophy, the risk of cardiovascular morbidity and 
mortality increased continuously as UAER augmented, without thresholds or 
plateaus (Gerstein et al 2001).  Based on the above, there is probably a necessity of 
shifting downward the limits for diagnosing microalbuminuria in Essential HT, 
starting well below the conventional cut off.  
At present LV hypertrophy is considered as potent marker of cardiovascular 
risk and an important surrogate end point in Essential hypertension.  According to 
several cross sectional studies, either by ECG or  echocardiography,  
microalbuminuric  patients exhibited a higher prevalence of LVH compared to 
normal albuminurics.  Vast majority of the reports supported the view that  
hypertensives with elevated  UAER had higher LV mass index; indicating that 
renal damage and LV hypertrophy are parallel phenomena.  Microalbuminuria is 
accompanied by concentric type of LV hypertrophy – LV condition with most 
adverse cardiovascular outcome.  Microalbuminuria has also been related, 
independent of the BP levels and LV mass with preclinical impairment of LV 
diastolic function; strengthening its role as a marker of early cardiac involvement 
 
 
 
 
in hypertensive populations.  A late study in 330 never treated non diabetic, 
hypertensives, showed a robust, graded, pressure independent link between 
increasing LV mass index and augmented UAER (Di Bello et al, 2003). The 
proposed cause for an elevated UAER in hypertensive patients with LVH is the 
increased levels of ANP secreted from the hypertrophied ventricles.  The fact that 
subjects with heart failure and elevated ANP levels exhibit microalbuminuria 
further supports this view.   
Hypertension induced structural and functional modification of large arteries 
may be directly related to the well recognized complication of Essential 
hypertension involving CNS, heart and kidneys.  The intima – media thickness of 
the carotid artery and the existence of atherosclerotic plaques and correlated to 
several cardiovascular risk factors and to the incidence of cardiovascular disease. 
Microalbuminuric subjects exhibit increased carotid artery wall intima – media 
thickness (IMT), higher frequency of plaques in arterial segments compared to 
normoalbuminuric subjects (Trepstar et al 2002) .    Arterial stiffness, the major 
determinant of central pulse pressure may be an independent marker of 
cardiovascular risk in Essential Hypertension.  High pulse pressure is closely 
associated with increase in urine albumin excretion rate.  Hypertensive patients 
with microalbuminuria have earlier systolic augmentation in carotid arterial 
 
 
 
 
pressure contour, reflecting increased arterial stiffness – this was proven in a study 
conducted in 162 hypertensive patients (Lambraou et al 2000).   
 Renal damage and microalbuminuria 
Microalbuminuria may be a predictor of progressive deterioration of renal 
function – as shown by some preliminary studies. In a few studies that examined 
the issue of relationship of microalbuminuria with increased risk of renal 
dysfunction, independent of BP levels and smoking habits, the results are rather 
conflicting.  More specifically, in one study, greater decline in renal function was 
observed in hypertensive subjects with microalbuminuria, where as other 
investigators found that increased renal albumin excretion rate has no renal 
prognostic significance. 
   The association of microalbuminuria with augmented cardiovascular risk 
may be explained at least partially by the frequent co existence of elevated UAER 
with a series of well established markers of cardiovascular risk such as 
dyslipidemia, non diabetic hyperglycemia, higher Body Mass Index, Central 
obesity; high serum uric acid; increased salt sensitivity, hyperhomocystinemia; 
dietary protein, smoking, sedentary life style, family history of essential 
hypertension, increased pulse pressure and absence of nocturnal BP decrease.( 
Garg et al 2002). 
 
 
 
 
    The role of inflammatory process as one of the pathophysiological links of  
microalbuminuria  with high cardiovascular states  cannot be ruled out.  Elevated 
UAER  is related to chronic low grade inflammation, the latter is closely associated 
with  unfavourable cardiovascular outcome and atherosclerosis, mediating all 
stages of atherosclerotic vascular disease form initiation to progression and 
ultimately thrombotic complications.  Significant  graded  relationship between BP 
and levels of inflammatory markers (IL – 6 and soluble ICAM – 1) were observed 
in healthy subjects.  Increased levels of vascular cell Adhesion molecule – 1 
(VCAM – 1), CRP  and fibrinogen are related to augmented UAER in diabetic and 
non diabetic subjects (Pannaciulli et al, 2001).  In certain cohorts, higher amounts 
of VCAM – 1 and CRP are related to microalbuminuria, more strongly in non 
diabetics than diabetics.  There was also positive relation with microalbuminuira, 
levels of diastolic BP and CRP levels in a study in which diabetic patients were 
excluded.  Till now there are no data from a trial  with only hypertensive subjects 
participating in it, there is cumulative evidence to support a possible relationship of 
microalbuminuria with markers of subclinical inflammation in the setting of 
essential HT. (Jager et al, 2002).   
 .  In a relatively small retrospective study, microalbuminuria predicted 
subsequent loss of renal function, despite similar baseline clinical characteristics 
and current BP levels through the study period (Bigazzi et al, 1998).     More 
 
 
 
 
recently, provocative data from a large cross sectional study indicate that high 
normal albuminuria (between 15 – 30mg/day) is associated with hyperfiltration in 
glomeruli (similar to diabetes), it could anticipate a decline in renal function 
(Veglio F et al, 1992).  In conclusion, although well conducted large prospective 
studies addressing this issue are yet to be carried out, the predictive value of 
microalbuminuria for hypertension – induced renal damage is at present a 
tempting, but speculative hypothesis8.   
Preserving cardiac function in hypertensive patient  - importance of renal 
parameters.  
Hypertensive cardiovascular disease is a systemic condition with potentially 
devastating long term effects on vascular and end organ function.  Although the 
foremost object of cardiologists concerned with its management is to protect 
patients against cardiac events and stroke, renal dysfunction is an integral 
component of the disease and a highly sensitive and predictive marker of its 
progress.  It is therefore surprising that, despite enormous diagnostic and 
therapeutic potential, renal considerations are still under utilized by cardiologists in 
the routine management of hypertension.  
Despite being readily available and amenable to intervention, renal 
parameters are under exploited in two key ways. Microalbuminuria measurement 
has yet to become routine for hypertensives, either within the clinic or in the 
 
 
 
 
general practice setting. It is a highly sensitive, readily assessed marker of incipient 
nephropathy and systemic endothelial pathology.  It is an independent predictor of 
either renal failure or cardiovascular morbidity and mortality.  Therefore, its 
measurement should be incorporated within standard management protocols for all 
patients with hypertension or diabetes.  
Sustained renal function should be a key goal of therapeutic intervention in 
early – stage disease for cardiologists as well as nephrologists. Agents that delay 
the progression of renal disease are likely to protect against adverse cardiovascular 
outcomes by protecting against the systemic consequences of renal disease and in 
addition, may exert beneficial effects on endothelia throughout the vasculature and 
in the heart.  
The relationship between renal and wider cardiovascular diseases is most 
evident in their advanced stages.  About half of the patients with congestive heart 
failure have chronic kidney disease, whereas congestive heart failure is about 15 
times more common in patients with chronic kidney disease than in patients with 
normal renal function. Congestive heart failure exacerbates nephropathy, whereas 
chronic kidney disease is associated with accelerated atherosclerosis, microvessel 
disease, endothelial dysfunction, and increased sympathetic activity and cardiac 
pathology. Renal artery stenosis and renovascular hypertension may also impact 
both on the non stenotic kidney and the heart.  
 
 
 
 
At the early stages of disease, when a patient may present with few overt 
pathologies other than hypertension, the relationship between renal and 
cardiovascular pathologies is also predictive of long term outcome and is more 
amenable to successful long term intervention. Vascular, cerebrovascular, and 
coronary diseases, ventricular hypertrophy, and ultimately, nephropathy and heart 
failure are all potential endpoints of a broad syndrome that is symptomatically 
silent for many years and involves a network of interlocked disease processes, 
which include sympathetic activation, haemodynamic changes, insulin resistance, 
inflammatory processes, dyslipidaemia, dysregulation of cytokines and growth 
factors, and consequent to many of these processes, endothelial damage.  One of 
the critical driving factors of this network is increased activity of the rennin 
angiotensin aldosterone system (RAAS), both within the kidney and vascular 
endothelium. One the basis of this pathophysiological role, it has been posited that 
RAAS blockade may provide a promising strategy for early therapeutic 
intervention in hypertensives with renal or atherosclerotic disease.  
There is abundant evidence that the occurrence of microalbuminuria in 
patients with hypertension or diabetes predicts adverse outcome.  The LIFE 
(Losartan Intevention For Endpoint reduction in hypertension) study in high risk 
hypertensives found that increased urinary albumin excretion is associated with left 
ventricular hypertrophy, abnormal geometry, and increased ventricular mass. The 
 
 
 
 
association was independent of blood pressure, diabetes, serum creatinine, age, or 
race, suggesting a close and direct correspondence between albuminuria and 
cardiac damage.  In the Heart Outcomes Prevention Evaluation (HOPE) Study, 
every 0.4mg/mmol/L increase in albumin: creatinine ratio increased the adjusted 
hazard for major cardiovascular events by 5.9%. Recently, the Prevention of Renal 
and Vascular End stage Disease (PREVEND) study demonstrated that fosinopril 
treatment vs. pravastatin significantly lowered urinary albumin excretion in 
patients with microalbuminuria and correspondingly was associated with a 40% (P 
= 0.098) reduction in cardiovascular events. Although this study did not enable the 
beneficial effects of reduced blood pressure per se and RAAS specific actions 
independent of blood pressure reduction to be distinguished, it is suggestive of a 
relationship between microalbuminuria and cardiovascular events.  
Thus,it is not surprising that microalbuminuria was found to be an excellent 
predictor of cardiovascular  morbidity and mortality in subjects with and without 
hypertension, in several prospective studies (31,32,33). 
From renoprotection to cardioprotection: the emerging role of RAAS 
blockade  
Since renal dysfunction is now known to be a core driver of cardiovascular 
pathology even at the earliest stages of hypertensive disease,  interventions that 
delay or reverse the  development of nephropathy should be integrated in the 
 
 
 
 
management of hypertension whenever microalbuminuria or frank proteinuiria are 
detected.  All agents that reduce systolic and diastolic blood pressures reduce 
albuminuria, but the most potent renoprotective drugs appear to be 
antihypertensive agents which block the RAAS. These agents selectively attenuate 
intra glomerular pressure by promoting vasodilatation of the glomerular efferent 
arterioles and favourably affect the regression remodeling and the improvement of 
endothelial function in resistance arterioles, particularly in patients with 
nephrosclerosis. A number of angiotensin converting enzyme (ACE) inhibitors and 
two angiotensin II receptor blockers (ARBs) irbesartan and losartan, have 
demonstrated renoprotective effects in major prospective trials.  New classes of 
agents, such as rennin inhibitors and selective aldosterone receptor antagonists, 
also have renoprotective potential, although these agents currently lack the support 
of large clinical trials data available for some ARBs and ACE-inhibitors. Further 
studies will be needed to characterize the most appropriate strategy using RAAS 
blockade across the spectrum from early to large – stage kidney disease.    
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 Study type :  Descriptive study 
Population: Adult  Systemic hypertension patients (inpatients/outpatients) , 
Department of General Medicine, Coimbatore Medical College Hospital. 
Duration : January 2008 to August 2009. 
Inclusion criteria : Patients with Systemic Hypertension {as defined  by The 
Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 7)} admitted in General 
Medicine wards or Outpatients,  not having any of the exclusion criteria. 
Exclusion criteria:  Pregnant women  ,those with diabetes mellitus(also impaired 
fasting glucose and impaired glucose tolerance),renal disease, urinary tract 
infection, raised blood urea and serum creatinine and macroproteinuria (albumin 
excretion more than 300 mg/24 hours), were excluded from the study 
Methodology :    Each participant was interviewed and examined in detail.     
1. History of hypertension given by the patients or relatives which was verified 
with previous records – OP tickets, or discharge cards. History of treatment 
for hypertension was also included.   
    
 
 
 
 
 
2. Newly detected Hypertensives:  Hypertension was diagnosed on the basis of 
the BP recorded in the arms with Mercury Sphygmomanometer:  Office 
measurements were used for OP patients.  For out patients, three recordings 
one week apart were used.  For inpatients, two recordings during the IP 
treatment period & one during their first review in OP were taken.  On each 
occasion, two readings were taken.  BP was taken with and the patient sitting 
relaxed, back supported, for five minutes and arm supported at the level of 
heart. All the recordings greater than 140/90mm Hg were regarded as 
Hypertension, which was confirmed at other occasions as mentioned above.  
3. A   detailed case record was prepared for each patient on the basis of specially 
designed proforma. The important factors considered in history were: the 
duration of hypertension and treatment; history of smoking; symptoms 
pertaining to cardiovascular and nervous system which could possibly suggest 
a target organ damage. 
4. Neurological symptoms considered were headache, seizure, altered sensorium, 
focal deficits or stroke.  Cardiovascular symptoms considered were dyspnoea, 
palpitation and chest pain. The duration of Hypertension was an important 
concern.   Hence the study population was divided into  four groups: 
1. Less than 1 year 
2.  1 to 5 years since diagnosis   
 
 
 
 
3.  5 -10 years since diagnosis  
4.  >10years since diagnosis- long duration 
This was an arbitrary division done for the ease of comparison.    
Based on the level of BP, the patients were divided into 3 groups as follows: 
1. Less than 140/90 mm Hg. (Adequate control with drug therapy) 
2. Systolic BP: 140 – 159 mm Hg 
 Diastolic BP :  90 – 99 mm Hg   -              Stage I of JNC 7 report 
3. Systolic BP : >160   mm Hg 
 Diastolic BP : >100 – 109 mm Hg                   Stage II of JNC 7 report 
Body mass index: 
Weight and height was measured for all ambulant patients and BMI 
expressed in Kg/m2.  Based on BMI, the study group was classified into:   
Under weight : <18.5  
Normal : 18.5 – 24.9 
Over weight : 25.0 – 29.9 
Obese : 30 – 39.9 
Extremely obese : >40 
Examination of all organ systems were done, with special emphasis on 
nervous system for any evidence of stroke and cardiovascular system for 
cardiomegaly or evidence of systolic  or diastolic dysfunction of heart. 
 
 
 
 
Fundus Examination: Done by direct ophthalmoscopy; pupillary dilatation 
achieved using 1% Tropicamide.  According to Fundus findings, the patients were 
divided into 6 groups. (Refer to Review of Literature): 
 
1. Fundus normal  
2. Fundus not visualized (Due to hazy media) 
3. Grade I Hypertensive Retinopathy  
4. Grade II Hypertensive Retinopathy 
5. Grade.III Hypertensive Retinopathy 
6. Grade.  IV Hypertensive Retinopathy 
Investigations done included: 
Random blood sugar,fasting and post prondial blood sugar was done in all 
patients to exclude diabetes. 
Serum creatinine and blood urea– Only those patients with normal value 
were taken up for the study. 
Urine examination – Albumin, RBC, WBC, Bacteria, Urine culture, ketones.  
Only those patients with normal urine examination results were included.   
Lipid profile (Fasting):  Was done for all patients.  They were divided into 
two groups. 
a. Favorable lipid profile  
Keith – Wagener Barker 
Classification  
 
 
 
 
b. Unfavorable lipid profile 
(Based on the LDL – C, HDL – C, TG   and total cholesterol values)   
The CHD risk was assessed on the basis of the ATP III guidelines of NCEP 
and the patients classified into different risk groups. LDL –C of the patients were 
compared with that of the goal set for each risk group to determine whether the 
lipid profile was favourable or unfavourable. 
Electrocardiogram: was taken for all patients to look for LVH.  The Sokolow 
– Lyon Index and the Romhilt – Estes point score system were used to 
diagnose LVH.  The patients satisfying the criteria of either of these were 
considered as having LVH. The two criteria were used together because of the 
low sensitivity of either of them taken alone (10 – 30%).   
Chest X – ray: was taken in all patients to look for cardiomegaly.  If the 
transverse dimension of the cardiac shadow exceeded 50% of that of the 
thorax, it was taken as cardiomegaly.   
CT Brain: was taken for all patients admitted with a clinical diagnosis of 
Stroke/ seizure/ or altered sensorium. 
Cardiac enzymes /Treadmill test as indicated for diagnosis of  Coronary 
artery disease 
Echocardiogram:  Done to assesstwo dimensional guided M-mode 
echocardiography was performed at the parasternal long axis view and apex; 
 
 
 
 
LVID at end systole & end diastole as well as IV septum and posterior wall 
thickness were assessed in accordance to the recommendations of American 
Society of echocardiography.  
1. LV Geometry → LVH present or not; based on the LV mass and relative wall 
thickness determined by M mode ECHO. Normal upper limit of LV mass 
(absolute value). Men – 259 g; Women – 166g.Concentric LV Hypertrophy 
was considered present if Relative wall thickness   was > 0.43 OR    LV Mass 
was increased. 
2. LV function: LV systolic/ diastolic dysfunction – were assessed on the basis of 
parameters mentioned previously.  
3. Chambers, valves, flow and regional wall motion were assessed. 
4. Wall motion abnormalities.   
Microalbuminuria::Aassessed by spot urine albumin: creatinine ratio (ACR) 
based on the recommendations of National Kidney Foundation and American 
Diabetic Association 1st voided midstream early morning sample of 5ml urine.   
Patients were asked to avoid exercise prior to collection, urine examination done in 
women in non menstrual phase.  Any value in between 30 – 300 μg/mg creatinine 
was taken as microalbuminuria. The data were analyzed using the program Epi 
Info® version 6.The chi-square(χ2) test  was used to compare variable prevalence 
between the groups, using a confidence interval of 95% (p<0.05). 
 
 
 
 
RESULTS & ANALYSIS 
A total of 100 hypertensive patients were studied. 
Table No:1 – Sex Distribution of  study group 
Sex No. of 
patients 
Percentage 
Male  49  49 
Female 51 51 
Figure No:1-Sex distribution of  study group 
 
Table No:2 - Distribution of microalbuminuria among males & female 
Microalbuminuria Total  
No: 
Gender  
  
p=0.08  
  χ2 = 2.89 
 Male  Female 
No. %    % 
 Present 27  17   62.9 10    37.1  
 Absent 73   32  43.8 41  56.2  
49
51
males
females
 
 
 
 
 Figure  No:2 - Distribution of microalbuminuria among males & female 
 
 
There was no statistically significant difference in the prevalence of 
microalbuminuria in male & female hypertensives. (p>0.05) 
 The mean systolic BP among study population was 142.9 mm of Hg while 
mean Diastolic BP was 88.2 mm of Hg.Relationship of microalbuminuria to 
duration of hypertension was studied. 
Table No:3 – Distribution of microalbuminuria among different groups – 
depending upon the duration of hypertension  
 
 
 
  
 
0
5
10
15
20
25
30
35
40
45
Count Count
male female
gender
microalbuminuria yes
microalbuminuria no
Microalbuminuria Total  
No: 
Duration of Hypertension(in 
years) 
p= <0.001 
χ2 =41.2 
   
 <1 1-5  5-10  >10 
 Present  27  2  9  15   1 
 Absent  63 36     28  7  2  
 
 
 
 
Figure No:3 – Distribution of microalbuminuria among different groups – 
depending upon the duration of hypertension  
 
 
There was statistically significant increase in the prevalence of microalbuminuria 
among patients with hypertension of long duration. (p<0.05) 
 
Table No:4 – Distribution of microalbuminuria among treated and untreated 
hypertensives  
  
Treatment Total  
No: 
Microalbuminuria  
p =0.94 
χ2 =0.03  
   
 Present Absent 
No. % No. % 
No 
Treatment 
 17  5  29.4  12 70.6  
Irregular 
treatment 
 38  10 26.3   28 73.7  
Regular 
treatment 
 45  12 26.6   33 73.4  
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Stroke and Microalbuminuria  
CT Brain was taken for  26 patients 
Indication were : Focal defects in 18 patients 
   Seizure in  2 patients 
   Altered sensorium in  6 patients 
CT findings:  
          Normal           - 5 patients 
Abnormal    –   21 patients 
 Haemorrhage   -  5 patients 
Infarct             -   16 patients    
 
 CT was not taken in 74 patients as their neurological examination was 
normal.  
 
Table No:10 –Distribution of Microalbuminuria in CVA   
 
CT brain Total 
No: of 
cases 
Microalbuminuria  
  
P =  0.61 
χ2 =0.25 
 present  absent 
No % No % 
Normal  5 2    40  3 60  
Abnormal  21  11  52.3 10   47.7 
Not taken  74  14  18.9  60   81. 1 
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Table No:13 –Coronary artery disease and Microalbuminuria 
  
 
 
 
 
 
 
 
 
 
 
Presence of coronary artery disease has significant correlation to presence of 
microalbuminuria in systemic hypertension 
 Figure No:13 –Coronary artery disease and Microalbuminuria 
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p =   <0.001 
χ2 =43.61 
 Present  absent 
No % No % 
No CAD  66  4   7.3 62  92.7  
 Stable 
angina 
 4 3  75  1    25 
Unstable 
angina 
 14 10   71.4  4    28.6  
Myocardial 
infarction 
16 10 62.5      6 37.5 
 
 
 
 
 Table No:14- Relationship of microalbuminuria with various target organ 
damages. 
Target organ damage P value 
 Retinopathy < 0.001 
 Left ventricular hypertrophy < 0.001 
 Left Ventricular dysfunction < 0.001 
Coronary artery disease <0.001 
Cerebrovascular accident 0.61 
 
 
 
 
 
 
 
 
 
 
Thus from above table ,we infer that presence of microalbuminuria has 
statistically significant association with development of retinopathy,left ventricular 
hypertrophy ,coronary artery disease and left ventricular dysfunction while study 
showed no correlation between development of stroke and presence of 
microalbuminuria in systemic hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
The present study evaluated the relationship of microalbuminuria with the 
indices of target organ damage in non diabetic hypertensives; correlation between 
microalbuminuria and age of the patient; duration and severity of hypertension and 
other cardiovascular risk factors.   
   Prevalence :  The prevalence of microalbuminuria in this  study was  27 %( 27 
out of 100 patients).  In 1991 Stefano Bianchi et al published  the first large study 
on the prevalence  of microalbuminuria  in hypertensives ; it was found to be – 
35%.   Palatini et al in HARVEST study and the PREVEND – IT (Prevention of 
Renal and Vascular End stage Disease – Study performed in the Dutch city of 
Groningen) showed a prevalence of 8 – 15%.  Another study by Tsioufis et al  in 
2002 reported a prevalence of 47%.,while that Stamm et al reported it as 13.7% in 
2006 49 .   The variability in prevalence  may be explained by 12:  
1. Different values used to define microalbuminuria. 
2. Different protocols used to evaluate microalbuminuria. 
3. Difference in the methods of urine collection. 
4. Characteristics of study population. 
 Sex distribution of microalbuminuria: In the present study, there was no 
significant difference between the prevalence of miroalbuminuria in men and 
women.[P= 0.08].  In the HUNT study (Norway) a stronger association was 
 
 
 
 
observed between  microalbuminuria and mortality in men than in women.  In this 
study the interaction between sex and Albumin creatinine Ratio (ACR) was 
statistically significant (p= 0.003) and supported a sex  difference, women had 
more prevalence.  They attributed this difference to the higher incidence of 
asymptomatic UTI in women.  They suggested the need for different ACR cut off 
values in men and women – because men have greater muscle mass and higher 
creatinine excretion than women although albumin excretion levels are equal13.  
(HUNT – Nord Trondelag Health Study).  Pontremoli et al in the MAGIC study on 
the prevalence and clinical correlates of microalbuminuria observed that 
microalbuminuria was more common in males.   
  In the present study,  microalbuminuria  was found to have positive  
correlation with the duration [P<0.05] but not to severity of Hypertension.[p 
=0.83]. Pontremoli et al 1997 in the MAGIC Study have observed  that degree and 
prevalence of microalbuminuria correlate with the height of BP when considering  
office values, even more  so with 24 hour B P    Cerasola et al and Ophsal et al had 
made similar observations21.    
Whether treatment of hypertension had any influence on microalbuminuria 
was studied.The difference in microalbuminuria in treated and untreated/irregularly 
treated hypertensives was not statistically significant.[p=0.94]. This observation 
may be due to the bias in classification of hypertensive patients to treated & 
 
 
 
 
untreated groups based on the treatment history; though many patients are on drug 
therapy, adequate control was not achieved in many.  
Microalbuminuria and other Cardiovascular risk factors:  The present study 
also looked into the relation between microalbuminuria and other risk factors for 
cardiovascular disease like smoking, obesity and unfavourable lipid profile.    
Significant correlation was observed between smoking and 
microalbuminuria.[p=0.005].  This observation is  concordant with that seen in 
previous studies on this aspect.    
Microalbuminuria had no positive correlation with BMI in the present 
study[P=0.714].  This is not in agreement with most of the previous studies. Del O’ 
mo et al (2003) had observed that microalbuminuria is more frequent in obese 
individuals. Leocini et al  had observed greater BMI in patients with 
microalbuminuria (p < 0.04)23,24.  Microalbuminuria was found to  have no relation  
with unfavorable  lipid profile(p=0.203).  This is not in agreement with previous 
studies.  Bianchi et al in 1997 had observed that   hypertensive patients with 
microalbuminuria manifest increased serum LDL level and greater LDL/HDL ratio 
when compared with patients without microalbuminuria and normotensives26.    
 
 
 
 
 
 
RELATIONSHIP OF MICROALBUMINURIA WITH THE INDICES OF 
TARGET ORGAN DAMAGE: 
Hypertensive Retinopathy  
The present study showed a significant correlation between 
microalbuminuria and the presence and severity of retinopathy. (p < 0.001).   
Beisen et al in 1997 has observed an increased prevalence of hypertensive 
retinopathy in a group with persistent microalbuminuria despite adequate 
treatment. (P < 0.03)21.  In 2002 Cerasola et al has observed a greater prevalence of 
Retinopathy among those patients with microalbuminuria27. 
Microalbuminuria and stroke 
The present study included  26 patients with  CNS involvement, 15 patients 
with CT showing infarct and 6 patients with CT showing hemorrhage,while 5 had 
normal CT study.Prevalence of microalbuminuria   had no association to  stroke (P 
= 0.61).  It is    contradictory to other studies which claim that microalbuminuria is 
a predictor of ischaemic stroke due to its well known association with carotid 
atherosclerosis (asymptomatic vascular events). There are many studies on the 
correlation between microalbuminuria and asymptomatic carotid artery disease – 
assessed by carotid intima – media thickness; Nuclear magnetic resonance imaging  
etc.  In a study by Pontrermoli et al (2002), out of 279 patients studied, Urine 
albumin excretion was positively associated with carotid atherosclerosis. Patients 
 
 
 
 
with increased UAE were 21 times more likely to develop increased carotid intima 
media thickness8.  Leena et al (Stroke – 1997) Observed increased carotid IMT in 
patients with microalbuminuria (P < 0.01).  In other studies, microalbuminuria has 
been shown to be a prognostic marker in ischemic stroke, even after accounting for 
confounding factors29,while the current study failed to show any association. 
Urine Albumin Excretion and Abnormalities in LV structure and function:  
It was  observed  that    23  out  of   100 (23%) patients  had  LVH   detectable   by  
ECHO. C. Tsioufis  et al [2002]  in  their  study observed  that 21% of the 249  had  
LVH. LVH  is  reported  in  nearly  30%  untreated hypertensives. 
In the present study, it was observed that there is significant correlation 
between the prevalence of microalbuminuria and the presence of LVH (P < 0.001) 
and LV dysfunction (P < 0.001) in hypertensive patients.    This aspect has been 
studied by many investigators. W.Kristian et al in 2002 (LIFE study) observed a 
higher prevalence of microalbuminuria 30% vs 9% in patients with concentric 
hypertrophy on ECHO (P < 0.0001)15. Pontremoli et al in 2002 has observed that 
patients with microalbuminuria were 21 times more likely to have both LVH (P < 
0.001) in a study conducted in 279 patients in their institution8.  C.Stefanadis et al 
made similar observation in 2002 – LVH was significantly higher in 
microalbuminuric patients compared with normoalbuminuric subjects (32 vs 5% p 
< 0.0001). The association between microalbuminuria and LV geometry may be  
 
 
 
 
 
due to hemodynamic or non hemodynamic reasons. It is suggested that 
increased levels of ANP secreted from hypertrophic ventricles can directly cause 
microalbuminuria.  The fact that subjects with heart failure and elevated ANP 
levels exhibit microalbuminuria gives further support to this view29. 
 
Microalbuminuria and coronary artery disease in systemic hypertension 
The study included 34 hypertensive patients with coronary artery 
disease.Microalbuminuria showed a positive correlation to presence of coronary 
artery disease.(p<0.001).This is in accordance to various international studies.The 
study by Jan Skov Jensen et al also clearly states that microalbuminuria in systemic 
hypertension is a predictor of coronary artery disease. Microalbuminuria is the 
strongest predictor of ischemic heart disease, with an unadjusted relative risk of 4.2 
(95% CI 1.5 to 11.9, P=0.006) and a relative risk of 3.5 (95% CI 1.0 to 12.1, 
P=0.05) when adjusted for all other atherosclerotic risk factors, including age and 
gender.  Study concludes that, microalbuminuria confers a 4-fold increased risk of 
ischemic heart disease among hypertensive or borderline hypertensive subjects.30, 44 
  
 
 
 
 
 
The data from this study thus support the positive correlation between 
microalbuminuria and the duration of hypertension,smoking; the  indices  of  target  
organ  damage (except cerebrovascular accident) and various other cardiovascular 
risk factors.          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
 Hypertension is a major health problem in the community  
 
 Microalbuminuria  has a positive  correlation with smoking,there by 
increasing risk of target organ damage in smoking population. 
 
 Prevalence of microalbuminuria is more in those with longer duration 
of  hypertension.  
 
 Microalbuminuria is an integrated marker of cardiovascular risk and 
has statistically significant correlation with the presence and severity 
of target organ damage in systemic hypertension like retinopathy,left 
ventricular hypertrophy,left ventricular dysfunction and coronary 
artery disease. 
 
 Microalbuminuria is a useful predictor of several target organ 
damages in systemic hypertension and hence should be utilized as a   
routine screening test in hypertensive population. 
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PROFORMA 
MICROALBUMINURIA IN  SYSTEMIC  HYPERTENSION  
AND ITS RELATIONSHIP TO TARGET ORGAN DAMAGE 
PROFORMA FOR DATA COLLECTION 
 
CASE NO:     NAME :        
 
NO:    AGE:      SEX:    
  
DURATION O HYPERTENSION : 
SYMPTOMS: 
 
PAST HISTORY: DIABETES MELLITUS/CHRONIC RENAL FAILURE/OTHER  CO-
MORBID ILLNESSES 
 
PAST ADMISSIONS:  
 
SMOKING:  
DURATION:   TYPE:   FREQUENCY:  
 
ALCOHOL INTAKE:          
DURATION:   AMOUNT:   TYPE : 
FREQURENCY:   
MENSTRUAL STATUS  
 
HEIGHT : WEIGHT:  BMI : 
 
PERIPHERAL PULSES:  
 
 
 
 
 
BP- SITTING:      STANDING : 
 
SYSTEMIC EXAMINATION- 
 
CVS     SKIN: 
 
 
RS:     EYE: 
 
 
ABD:     BONE: 
  
 
CNS:     FOOT: 
   
 
PNS:     DENTAL: 
LABORATORY EXAMINATION 
 
URINE 
 
ALB:  SUGAR:  ACETONE:  PUS CELLS: 
 
URINE CULTURE & SENSITIVITY: 
 
URINE ALBUMIN/CREATININE RATIO: 
 
 
 
 
 
BLOOD 
 
HB:  TC:  DC:  ESR:  PLATELETS: 
 
UREA:  CR:  FBG:  PPBG: 
 
CHOL:  TG:  HDL:  LDL: 
 
ECG 
 
 
CHEST X-RAY 
 
 
OPTIC FUNDUS 
 
 
ECHOCARDIOGRAPHY 
 
 
CT BRAIN 
 
 
 DETAILS OF  DRUG THERAPY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT FORM 
Project title: 
“MICROALBUMINURIA IN SYSTEMIC HYPERTENSION AND ITS 
RELATIONSHIP TO TARGET ORGAN DAMAGE ”  
This is a project to detect the prevalence of   microalbuminuria in systemic 
hypertension and its relationship to target organ damage Your participation will 
help us to identify the presence of  microalbuminuria in hypertension  and will help 
in  appropriate interventions.All information collected from you for this purpose 
will be kept confidential and names will not be disclosed. 
I _________________________ fully understand the project and have no objection 
in the researchers using any of my information for the purpose of research. My 
signature below indicates that I voluntarily agree to participate in this study. I will 
receive a copy of this consent form. 
Name of the worker:  
Name of the witness:  
Signature of the worker:  
Signature of the witness:                                                          
Date  : 
 
 
 
 
 
 
 ABBREVIATIONS 
 
 ACEI: Angiotensin Converting Enzyme Inhibitors 
ACR: Albumin Creatinine Ratio 
ARB: Angiotensin Receptor Blocker 
BMI:Body Mass Index 
BP : Blood Pressure 
BUN: Blood Urea Nitrogen 
CAD: Coronary Artery Disease 
CCF: Congestive Cardiac Failure 
CT: Computerised Tomography 
CVA:Cerebro Vascular Accident 
DBP: Diastolic Blood Pressure 
ECG: Electrocardiogram 
HDL:  High-Density Lipoprotein 
HT: Hypertension 
JNC: Joint National committee 
 
 
 
 
LDL: Low-Density Lipoprotein 
LV: Left Ventricle 
LVH: Left Ventricular Hypertrophy 
MI: Myocardial Infarction 
MRI: Magnetic Resonance Imaging 
RAAS: Renin-Angiotensin-Aldosterone System 
SBP: Systolic Blood Pressure 
TG: Triglycerides 
UAE: Urine Albumin Excretion 
 
 
 
 
   
 
 
